Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Issue 5 (October 2016)

• Record Type: Journal Article
• Authors: Mazereeuw, Graham; Herrmann, Nathan; Oh, Paul I.; Ma, David W.L.; Wang, Cheng Tao; Kiss, Alexander; Lanctôt, Krista L.
• Is Part Of: Journal of clinical psychopharmacology. Volume 36:Issue 5(2016)
• Publication Date: 2016-10
• Subjects: EPA -- eicosapentaenoic acid -- DHA -- docosahexaenoic acid -- depression -- mood -- affect -- memory -- cognitive impairment -- exercise -- fish oil -- cardiac rehabilitation -- fitness -- attention -- executive function; Psychopharmacology -- Periodicals; Psychopharmacology -- Periodicals; Psychopharmacologie -- Périodiques; Psychopharmacology; Periodicals; 615.78
• DOI: 10.1097/JCP.0000000000000565
• Languages: English
• ISSNs: 0271-0749

Abstract

Abstract : Abstract: This trial investigated the efficacy of omega-3 polyunsaturated fatty acid (n-3 PUFA) treatment for improving depressive symptoms and cognitive performance in patients with coronary artery disease (CAD) participating in cardiac rehabilitation. Patients with CAD aged 45 to 80 years were randomized to receive either 1.9-g/d n-3 PUFA treatment or placebo for 12 weeks. Depressive symptoms were measured using the Hamilton Depression Rating Scale (HAM-D, primary outcome) and the Beck Depression Inventory II (BDI-II). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria were used to identify a depressive episode at baseline. Cognitive performance was measured using a standardized battery for vascular cognitive impairment. In 92 patients (age, 61.7 ± 8.7 y; 76% male, 40% depressed; HAM-D, 6.9 ± 5.9; BDI-II, 12.3 ± 10.9; n = 45 n-3 PUFA, n = 47 placebo), depression decreased (HAM-D, F 3, 91 = 2.71 and P = 0.049; BDI-II, F 3, 91 = 6.24 and P < 0.01), and cognitive performance improved (attention/processing speed, F 1, 91 = 5.57, P = 0.02; executive function, F 1, 91 = 14.64, P < 0.01; visuospatial memory, F 1, 91 = 4.01, P = 0.04) over cardiac rehabilitation. Omega-3 PUFA treatment increased plasma eicosapentaenoic acid ( F 1, 29 = 33.29, P < 0.01) and docosahexaenoic acid ( F 1, 29 = 15.29, P < 0.01) concentrations but did not reduce HAM-D ( F 3, 91 = 1.59, P = 0.20) or BDI-II ( F 3, 91 = 0.46, P = 0.50) scores compared with placebo. Treatment did not improve cognitive performance; however, n-3 PUFAs significantly increased verbal memory compared with placebo in a subgroup of nondepressed patients ( F 1, 54 = 4.16, P = 0.04). This trial suggests that n-3 PUFAs do not improve depressive and associated cognitive symptoms in those with CAD. The possible benefits of n-3 PUFAs for verbal memory may warrant investigation in well-powered studies.